{"schema_version":"1.0","type":"article","title":"半年併購 1,340 億美元：Big Pharma 到底在搶什麼？","url":"https://drugnews.com.tw/articles/2026-07-05-big-pharma-134b-biotech-ma.html","markdown_url":"https://drugnews.com.tw/articles/2026-07-05-big-pharma-134b-biotech-ma.md","lang":"zh-Hant","date":"2026-07-05","publish_at":"2026-07-05T04:10:13.005Z","updated_at":"2026-07-05","category":"商業分析系列","topic":"商業分析系列","tags":["商業分析系列","免費文章","BD","併購","臨床數據","生技投資","製藥巨頭","新藥開發","生技估值"],"summary":"2026 年才過一半，全球製藥業的併購節奏已經快到讓人有點恍神。","key_points":[],"facts":[],"sections":["01｜Big Pharma 買的不是公司，是時間","02｜買家不再為故事買單，只為「去風險」買單","03｜併購回暖，不等於所有 Biotech 都春天來了","04｜買得多，不代表買得準","結語｜Big Pharma 不是突然更有錢，而是越來越等不起"],"references":[{"title":"[0]: 各公司官網與公開資料","source":"","date":"","url":""},{"title":"[1]: AbbVie / Apogee 交易公開報導","source":"","date":"","url":""},{"title":"https://www.marketwatch.com/story/abbvie-would-gain-an-experimental-eczema-drug-by-buying-biotech-report-caf24728","source":"","date":"","url":"https://www.marketwatch.com/story/abbvie-would-gain-an-experimental-eczema-drug-by-buying-biotech-report-caf24728"},{"title":"[2]: GSK / Nuvalent 交易公開報導","source":"","date":"","url":""},{"title":"https://www.barrons.com/articles/nuvalent-stock-gsk-deal-89443e68","source":"","date":"","url":"https://www.barrons.com/articles/nuvalent-stock-gsk-deal-89443e68"},{"title":"[3]: Eli Lilly / 4E Therapeutics 交易公開報導","source":"","date":"","url":""},{"title":"https://www.barrons.com/articles/eli-lilly-stock-painkillers-acquisition-8da0dbbe","source":"","date":"","url":"https://www.barrons.com/articles/eli-lilly-stock-painkillers-acquisition-8da0dbbe"},{"title":"[4]: 2026 年上半年製藥 / Biotech M&A 統計，依原始社群公開稿引用之產業統計資料整理。","source":"","date":"","url":""},{"title":"[5]: Pfizer sigvotatug vedotin 三期試驗未達主要終點相關公開報導","source":"","date":"","url":""},{"title":"https://www.reuters.com/business/healthcare-pharmaceuticals/pfizers-experimental-lung-cancer-drug-fails-late-stage-study-2026-06-30/","source":"","date":"","url":"https://www.reuters.com/business/healthcare-pharmaceuticals/pfizers-experimental-lung-cancer-drug-fails-late-stage-study-2026-06-30/"}],"images":[{"alt":"Facebook 原圖：半年併購 1,340 億美元：Big Pharma 到底在搶什麼？（圖 1）","url":"https://drugnews.com.tw/assets/articles/big-pharma-134b-biotech-ma/facebook-01.png"},{"alt":"Facebook 原圖：半年併購 1,340 億美元：Big Pharma 到底在搶什麼？（圖 2）","url":"https://drugnews.com.tw/assets/articles/big-pharma-134b-biotech-ma/facebook-02.png"},{"alt":"Facebook 原圖：半年併購 1,340 億美元：Big Pharma 到底在搶什麼？（圖 3）","url":"https://drugnews.com.tw/assets/articles/big-pharma-134b-biotech-ma/facebook-03.png"},{"alt":"Facebook 原圖：半年併購 1,340 億美元：Big Pharma 到底在搶什麼？（圖 4）","url":"https://drugnews.com.tw/assets/articles/big-pharma-134b-biotech-ma/facebook-04.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/big-pharma-134b-biotech-ma/cover.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-07-05）。半年併購 1,340 億美元：Big Pharma 到底在搶什麼？。https://drugnews.com.tw/articles/2026-07-05-big-pharma-134b-biotech-ma.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-07-05-big-pharma-134b-biotech-ma-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}